Michigan is currently home to 2187 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Registry of the Patient Experience for Carpal Tunnel Release
Recruiting
Multi-center study to collect large scale, multidimensional real-world data on patients undergoing carpal tunnel release (CTR).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Mendelson Orthopedic PC (CTR-US), Troy, Michigan
Conditions: Carpal Tunnel Syndrome, CTS
The Fourth Left Atrial Appendage Occlusion Study
Recruiting
LAAOS-4 aims to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving ongoing treatment with oral anticoagulation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism
SMART TRENDS Study
Recruiting
A multicenter, interventional, feasibility comparison with historical controls
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Moderate to High-risk Noncardiac Surgery
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
Recruiting
This is an open-label, single-arm, multicenter clinical study to evaluate the effectiveness and safety of risdiplam administered as an early intervention in pediatric participants with spinal muscular atrophy (SMA) and 2 SMN2 copies who have previously received onasemnogene abeparvovec. Participants are children \< 2 years of age genetically diagnosed with SMA.
Gender:
ALL
Ages:
Between 3 months and 24 months
Trial Updated:
05/16/2025
Locations: Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan
Conditions: Muscular Atrophy, Spinal
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
05/16/2025
Locations: Research Site, Ann Arbor, Michigan
Conditions: Breast Cancer, Early Breast Cancer
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
Recruiting
This study is a prospective, multicenter, randomized controlled trial of an interventional strategy using the ClotTriever System to achieve and maintain vessel patency (ClotTriever Intervention Arm) versus conservative medical management using anticoagulation therapy alone (Conservative Medical Management Arm) in the treatment of subjects with symptomatic unilateral iliofemoral DVT. The study will collect data on demographics, comorbidities, details from the DVT diagnosis and treatment, and clin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: McLaren Healthcare, Bay City, Michigan
Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
Recruiting
This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: University of Michigan Cancer Center, Ann Arbor, Michigan
Conditions: KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic, Malignant Neoplasm of Pancreas
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/16/2025
Locations: AA Medical Research Center-Grand Blanc, Grand Blanc, Michigan
Conditions: Systemic Lupus Erythematosus
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
Recruiting
The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: High-risk Large B-cell Lymphoma (LBCL)
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
Recruiting
ABN401-003 is a Phase 2 clinical study to assess efficacy, safety, tolerability and pharmacokinetic profile of ABN401 (vabametkib) in specific populations of advance solid tumors with c-MET alterations as monotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: The Henry Ford Cancer Institute, Detroit, Michigan
Conditions: Advanced Solid Tumors
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome
Recruiting
This phase IIb trial tests whether Tri-Ad5 in combination with N-803 works to prevent colon and other cancers in participants with Lynch syndrome. Each of the three injections in Tri-Ad5 vaccine contain a different substance that is in precancer and cancer cells. Injecting these substances may cause the immune system to develop a defense against cancer that recognizes and destroys any precancer and cancer cells that produce these proteins in the future. N-803 may increase immune responses to oth... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Conditions: Lynch Syndrome, Colorectal Carcinoma, Colorectal Neoplasm
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Recruiting
This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conducted in subjects whose tumors are Cyclin E1 positive as determined by central review using the Sponsor's investigational clinical trial assay.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Site 0228 - Corewell Health Medical Group West, Grand Rapids, Michigan
Conditions: High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer